Ginna MD - CARGO Therapeutics, Chief Officer
| CRGX Stock | 16.23 0.50 3.18% |
Executive
Ginna MD is Chief Officer of CARGO Therapeutics, Common
| Age | 59 |
| Address | 1900 Alameda De Las Pulgas, San Mateo, CA, United States, 94403 |
| Phone | 650-379-6143 |
| Web | https://cargo-tx.com |
CARGO Therapeutics, Management Efficiency
The company has return on total asset (ROA) of (0.4035) % which means that it has lost $0.4035 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6981) %, meaning that it created substantial loss on money invested by shareholders. CARGO Therapeutics,'s management efficiency ratios could be used to measure how well CARGO Therapeutics, manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.23 in 2024. Return On Capital Employed is likely to drop to -0.24 in 2024. At this time, CARGO Therapeutics,'s Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 45.7 M in 2024, whereas Other Current Assets are likely to drop slightly above 1.4 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| MD MBA | Eliem Therapeutics | 50 | |
| Kim Fox | Milestone Pharmaceuticals | N/A | |
| Caroline Holda | Seres Therapeutics | N/A | |
| MD FAAP | Lumos Pharma | N/A | |
| John PharmD | Scpharmaceuticals | N/A | |
| RPh Young | Seres Therapeutics | 57 | |
| Michael Hassman | Scpharmaceuticals | N/A | |
| Matthew Henn | Seres Therapeutics | 49 | |
| David Ege | Seres Therapeutics | 49 | |
| Eddie MBA | Lumos Pharma | N/A | |
| Roshan Girglani | Milestone Pharmaceuticals | N/A | |
| Lisa MD | Seres Therapeutics | 65 | |
| Nishi MD | Eliem Therapeutics | N/A | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
| Lee Flowers | HCW Biologics | 78 | |
| Carlo Tanzi | Seres Therapeutics | N/A | |
| Steve Parsons | Scpharmaceuticals | N/A | |
| Rachael Nokes | Scpharmaceuticals | 49 | |
| Nicole Esq | HCW Biologics | N/A | |
| JD Esq | Seres Therapeutics | 69 | |
| Jeffrey Nelson | Milestone Pharmaceuticals | 43 | |
Management Performance
| Return On Equity | -0.7 | ||||
| Return On Asset | -0.4 |
CARGO Therapeutics, Leadership Team
Elected by the shareholders, the CARGO Therapeutics,'s board of directors comprises two types of representatives: CARGO Therapeutics, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CARGO. The board's role is to monitor CARGO Therapeutics,'s management team and ensure that shareholders' interests are well served. CARGO Therapeutics,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CARGO Therapeutics,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gina Chapman, CEO President | ||
| Crystal MD, CoFounder Chair | ||
| JD Esq, Chief Officer | ||
| Ginna MD, Chief Officer | ||
| Faisal MBA, Senior Accounting | ||
| Louai Labanieh, Founder | ||
| Michael Ports, Chief Officer | ||
| Shishir Gadam, Chief Officer | ||
| Brett Masterson, Head Marketing | ||
| Anup Radhakrishnan, Secretary CFO | ||
| Nancy JD, Founder | ||
| Robbie MD, CoFounder Member | ||
| MPH MD, Chief Officer |
CARGO Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CARGO Therapeutics, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.7 | ||||
| Return On Asset | -0.4 | ||||
| Current Valuation | 370.77 M | ||||
| Shares Outstanding | 46.03 M | ||||
| Shares Owned By Insiders | 4.80 % | ||||
| Shares Owned By Institutions | 95.20 % | ||||
| Number Of Shares Shorted | 5.57 M | ||||
| Price To Book | 1.86 X | ||||
| EBITDA | (93.02 M) | ||||
| Net Income | (98.15 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for CARGO Stock Analysis
When running CARGO Therapeutics,'s price analysis, check to measure CARGO Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CARGO Therapeutics, is operating at the current time. Most of CARGO Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of CARGO Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CARGO Therapeutics,'s price. Additionally, you may evaluate how the addition of CARGO Therapeutics, to your portfolios can decrease your overall portfolio volatility.